Southpoint Capital Advisors LP lifted its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 57.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 110,000 shares of the biopharmaceutical company’s stock after purchasing an additional 40,000 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 2.0% of Southpoint Capital Advisors LP’s investment portfolio, making the stock its 24th biggest position. Southpoint Capital Advisors LP owned 0.10% of Regeneron Pharmaceuticals worth $41,356,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC grew its holdings in shares of Regeneron Pharmaceuticals by 495.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 307 shares during the period. Advisory Services Network LLC grew its holdings in shares of Regeneron Pharmaceuticals by 147.0% during the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 266 shares during the period. Vident Investment Advisory LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $200,000. Moors & Cabot Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $217,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $204,000. Institutional investors and hedge funds own 66.40% of the company’s stock.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $325.60, for a total value of $325,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 10.80% of the company’s stock.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at $341.70 on Monday. The stock has a market capitalization of $36,799.72, a P/E ratio of 24.73, a P/E/G ratio of 1.07 and a beta of 1.54. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.18 and a current ratio of 3.82. Regeneron Pharmaceuticals Inc has a 12 month low of $313.53 and a 12 month high of $543.55.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share for the quarter, beating the consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The company had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.50 billion. During the same period last year, the business posted $3.04 EPS. The company’s revenue was up 28.9% on a year-over-year basis. analysts expect that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc (REGN) Shares Bought by Southpoint Capital Advisors LP” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/03/12/regeneron-pharmaceuticals-inc-regn-shares-bought-by-southpoint-capital-advisors-lp.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.